

Supplemental Table 1: Association between Non-HLA T1D Candidate SNPs and Development of IA, Progression from IA to T1D, and Development of T1D Unadjusted for HLA-DR3/4,DQB1*0302 and First Degree Relative with T1D.

SNP	Development of IA (n = 1619)		Progression from IA to T1D (n = 132)		Development of T1D (n = 1619)	
	HR and 95% CI	P Value	HR and 95% CI ^a	P Value	HR and 95% CI	P Value
<i>CIQTNF6</i> (rs229541)	1.55 (1.18, 2.02)^b	0.001	1.25 (0.86, 1.83) ^b	0.25	1.94 (1.33, 2.84)^b	0.001
<i>C6orf173</i> (rs9388489)	1.16 (0.88, 1.52) ^b	0.29	0.93 (0.68, 1.27) ^b	0.66	1.05 (0.70, 1.56) ^b	0.83
<i>C14orf181</i> (rs1465788)	1.00 (0.77, 1.31) ^b	0.98	1.04 (0.59, 1.84) ^c	0.89	0.79 (0.46, 1.39) ^c	0.42
<i>IL2</i> (rs2069762)	1.06 (0.80, 1.40) ^b	0.69	1.33 (0.88, 2.00) ^b	0.18	1.19 (0.78, 1.81) ^b	0.42
<i>IL2</i> (rs4505848)	1.02 (0.79, 1.32) ^b	0.88	0.93 (0.66, 1.30) ^b	0.66	1.16 (0.80, 1.68) ^b	0.43
<i>IL2RA</i> (rs12722563)	0.83 (0.53, 1.30) ^c	0.41	0.63 (0.23, 1.72) ^c	0.37	0.37 (0.15, 0.92)^c	0.03
<i>IL2RA</i> (rs2104286)	0.82 (0.60, 1.10) ^b	0.19	1.04 (0.59, 1.83) ^c	0.90	0.66 (0.37, 1.19) ^c	0.17
<i>IL7R</i> (rs6897932)	0.93 (0.68, 1.29) ^b	0.67	0.88 (0.51, 1.51) ^c	0.64	0.84 (0.48, 1.49) ^c	0.55
<i>PRKCQ</i> (rs947474)	1.11 (0.74, 1.65) ^c	0.62	0.64 (0.36, 1.12) ^c	0.12	0.75 (0.40, 1.42) ^c	0.38
<i>SKAP2</i> (rs7804356)	0.90 (0.66, 1.22) ^b	0.49	1.32 (0.78, 2.24) ^c	0.31	0.96 (0.54, 1.69) ^c	0.88
<i>SMARCE1</i> (rs7221109)	0.94 (0.71, 1.23) ^b	0.63	0.88 (0.51, 1.51) ^b	0.63	0.69 (0.41, 1.16) ^b	0.16
<i>TLR8</i> (rs5979785) ^d	0.84 (0.64, 1.09) ^b	0.18	0.90 (0.65, 1.26) ^b	0.54	0.92 (0.63, 1.34) ^b	0.66
<i>UBASH3A</i> (rs3788013)	1.22 (0.92, 1.63) ^b	0.17	1.28 (0.88, 1.87) ^b	0.20	1.76 (1.15, 2.69)^b	0.01
rs10517086	*	*	1.60 (0.89, 2.87) ^c	0.12	1.90 (1.28, 2.83)^b	0.002

Abbreviations: CI, confidence interval; DAISY, Diabetes Autoimmunity Study in the Young; HLA, human leukocyte antigen; HR, hazard ratio; IA, islet autoimmunity; MAF, minor allele frequency; T1D, type 1 diabetes.

^aAdjusted for age at first autoantibody positive visit.

^bSNP analyzed additively with HR representing increase in risk for each additional minor allele.

^cSNP analyzed dichotomously with HR representing increase in risk for at least one minor allele.

^d*TLR8* (rs5979785) is adjusted for sex because it is on the X chromosome.

*SNP rs10517086 did not meet the assumptions of proportional hazards in the development of IA analysis.